Literature DB >> 21127879

Should we really compare absolute risk reduction in different trials on osteoporosis: comment on the article by Ringe JD and Doherty JG.

Zhanna E Belaya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21127879     DOI： 10.1007/s00296-010-1626-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  13 in total

1.  Could strontium ranelate have a synergistic role in the treatment of osteoporosis?

Authors:  Glen M Blake; Juliet E Compston; Ignac Fogelman
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

2.  Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Authors:  J Y Reginster; E Seeman; M C De Vernejoul; S Adami; J Compston; C Phenekos; J P Devogelaer; M Diaz Curiel; A Sawicki; S Goemaere; O H Sorensen; D Felsenberg; P J Meunier
Journal:  J Clin Endocrinol Metab       Date:  2005-02-22       Impact factor: 5.958

3.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

4.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

Review 5.  Bisphosphonates and osteoporotic fractures: a cross-design synthesis of results among compliant/persistent postmenopausal women in clinical practice versus randomized controlled trials.

Authors:  M M Wilkes; R J Navickis; W W Chan; E M Lewiecki
Journal:  Osteoporos Int       Date:  2009-07-02       Impact factor: 4.507

6.  Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment.

Authors:  Chenghao Li; Oskar Paris; Stefan Siegel; Paul Roschger; Eleftherios P Paschalis; Klaus Klaushofer; Peter Fratzl
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

7.  Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Authors:  Charles H Chesnut; Arne Skag; Claus Christiansen; Robert Recker; Jacob A Stakkestad; Arne Hoiseth; Dieter Felsenberg; Hermann Huss; Jennifer Gilbride; Ralph C Schimmer; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

8.  The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Authors:  Pierre J Meunier; Christian Roux; Ego Seeman; Sergio Ortolani; Janusz E Badurski; Tim D Spector; Jorge Cannata; Adam Balogh; Ernst-Martin Lemmel; Stig Pors-Nielsen; René Rizzoli; Harry K Genant; Jean-Yves Reginster
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

9.  Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Authors:  Robert R Recker; Fernando Marin; Sophia Ish-Shalom; Rüdiger Möricke; Federico Hawkins; Georgios Kapetanos; María P de la Peña; Jörn Kekow; Jordi Farrerons; Beatriz Sanz; Heide Oertel; Jan Stepan
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

Review 10.  Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat.

Authors:  Johann D Ringe; John G Doherty
Journal:  Rheumatol Int       Date:  2009-12-25       Impact factor: 2.631
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.